PVLA: Palvella Therapeutics, Inc.
Performance
PVLA +123.67%
Watchlist
Select an item
Summary
PVLA at a glance
PVLA returned +123.67% over the past year. Its worst drop in that year was -31.11%, smaller than 55% of stocks on Redstone, and its Sharpe ratio of 1.32 beats 87% of stocks on Redstone. It pays no dividends.
Current Drawdown
-1.05%
Rolling Volatility
74.67%
Actions
Metrics
Risk Indicators
Alpha95.04%
Beta1.66x
Sharpe1.32
Sortino2.22
Omega1.27
Calmar3.98
Martin7.42
Profile
About PVLA
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $2.5B
- Listed
- Dec 2024
- Employees
- 29
- Headquarters
- Wayne, PA
- Website
- palvellatx.com
Comparisons